Myeloproliferative Neoplasms
The research activity is centered on myelofibrosis, with attention to patients who have thrombocytopenia and reduced platelet counts. This reflects a focused interest in chronic myeloproliferative disorders and their clinical burden.
- Myelofibrosis
- Thrombocytopenia
- Platelet count abnormalities
Clinical activity in this area is supported through collaboration across multiple research sites in Spain.
Bone Marrow Fibrosis
The sponsor’s trial portfolio includes interest in the bone marrow changes associated with fibrosis, highlighting disease features that affect marrow structure and function in myelofibrosis.
- Bone marrow fibrosis
- Marrow microenvironment
- Fibrotic disease features
This area connects hematologic disease management with the assessment of structural marrow involvement.
Hematology
Research interest extends to specialized hematology, particularly conditions involving abnormal blood cell production and low platelet levels. The clinical focus is aligned with the care of patients affected by chronic marrow disorders.
- Chronic hematologic disease
- Blood cell production disorders
- Thrombocytopenic hematologic conditions
The sponsor’s activity is concentrated in a single-country setting with active patient recruitment.
Targeted Therapeutic Development
The funded research landscape includes treatment evaluation in myelofibrosis with low platelet counts, indicating interest in therapies designed for patients with limited hematologic reserve and complex disease features.
- Therapeutic evaluation in myelofibrosis
- Patients with thrombocytopenia
- Hematologic treatment response
Activity is coordinated through the GEMFIN Secretariat in Barcelona, with participation from 13 collaborating research sites.
